Navigation Links


Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

6/1/2015
CHICAGO and RARITAN, N.J. , June 1, 2015  Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival (PFS) with trabectedin (YONDELIS ® ) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously t... [Comments]

GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting

6/1/2015
CHICAGO , June 1, 2015 GenomeDx Biosciences today announced that the robust Decipher® genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool t... [Comments]

Global Bio-alcohols Market 2015-2019

6/1/2015
NEW YORK , June 1, 2015 About Bio-alcohols Bio-alcohols are organic compounds produced by the fermentation of sugar or cellulose. Bio-alcohols are primarily used in the transportation sector. For instance, bio-ethanol can be used as a replacement for gasoline in cars. Technavio's analysts forecast the global bio-alcohols market to grow at a CAGR of 9 percent over the period... [Comments]

Biorem Reports Increased Revenues and Earnings for First Quarter

6/1/2015
GUELPH, ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for the three month period ended March 31, 2015.  Biorem's complete 2015 first quarter financial statements and MD&A have been filed on SEDAR ( www.sedar.com ). Financial Summary:Three-months ended March 31,(in CDN$'000 except per share data) 2015... [Comments]

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

6/1/2015
EAST HANOVER, N.J. , June 1, 2015  Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma. Findings from the ongoing study conducted by the University of Pennsylvania's Perelman Sch... [Comments]

Global PDT Machine Industry Report 2014

6/1/2015
DUBLIN , June 1, 2015 Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ) has announced the addition of the "Global PDT Machine Industry Report 2014" report to their offering.        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The Global PDT Machine Industry Report 2014 is a professional and... [Comments]

Val Skinner Foundation Announces Partnership With Discovery Education

6/1/2015
BAY HEAD, N.J. , June 1, 2015  The Val Skinner Foundation is partnering with Discovery Education to launch a national innovative science curriculum for high school students focused on cancer genetics. Skinner made the announcement at the 16 th annual LIFE Event (LPGA Pros in the Fight to Eradicate breast cancer) held at Mountain Ridge Country Club in West Caldwell, N.J.... [Comments]

Regis Technologies Offers Chiral Chromatography Service

6/1/2015
Morton Grove, IL (PRWEB) June 01, 2015 Regis Technologies, Inc. is a recognized leader in developing and manufacturing of chiral stationary phases (CSPs) for analytical and preparative chromatography separations. Expanding the options for its current and presenting solutions for new clients, Regis implemented a Chiral Separation Service to its portfolio. This valuable addition to its core e... [Comments]

Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics

6/1/2015
DUBLIN , May 29, 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ) has announced the addition of the "Global Bioinformatics Market 2015-2019" report to their offering. The analysts forecast the global bioinformatics market to grow at a CAGR of 19.49% over the period 2014-2019. Bioinformatics is a field of science that includes computat... [Comments]

Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting

6/1/2015
RESEARCH TRIANGLE PARK, N.C. , June 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cis... [Comments]

[previous] [next]
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Venus Express has detected the molecule hydroxyl on another ... an important new tool to unlock the workings of ... molecule, is made up of a hydrogen and oxygen ... reaches of the Venusian atmosphere, some 100 km above ...
... to stave off the cognitive deficits that occur with ... published in the second issue for May of the ... Care Medicine. Researchers examined the effects green tea ... were intermittently deprived of oxygen during 12-hour night cycles, ...
... the Great Lakes with things like trout and salmon would be ... the water, so it would be natural to assume that more ... in the April journal of Ecology by the Ecological Society of ... and trout to the area has not been good for the ...
Cached Biology News:Key molecule discovered in Venus's atmosphere 2Green tea compounds beat OSA-related brain deficits 2Restoring fish populations leads to tough choice for Great Lakes Gulls 2
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... is a preparation of deoxyribonuclease I ... to produce 3-hydroxyl oligonucleotides. This preparation ... where maintaining the integrity of RNA ... for use with the Core Footprinting ...
Biology Products:
(Date:6/1/2015)... , June 1, 2015 GenomeDx ... genomic analysis platform, successfully classified various subtypes ... expression of certain biomarkers, including one type ... this unique genomic signature has potential as ... neoadjuvant chemotherapy in patients with muscle-invasive bladder ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... Grove, IL (PRWEB) June 01, 2015 ... in developing and manufacturing of chiral stationary phases ... the options for its current and presenting solutions ... Service to its portfolio. This valuable addition to ... fast and effective advantage that can tackle projects ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
Breaking Biology Technology:GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3
... ... Spectrum Software announces key hire. Cindy Larkin has been hired as Director of ... her new role. , ... Southborough, MA (Vocus) November 3, 2009 -- Leading medical device and life sciences ...
... 2 BioBehavioral Diagnostics Company announced today that its ... was accepted via a rigorous peer-review process and included ... Meeting of the American Academy of Child and Adolescent ... Calvin R. Sumner, M.D., the company,s Chief Medical Officer ...
... 2 Microfluidics International Corporation (OTC Bulletin Board: MFLU), ... ended September 30, 2009. , (Logo: ... accomplishments: , Earned net income for the ... before interest, taxes, depreciation and amortization (EBITDA) Delivered ...
Cached Biology Technology:Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 2Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 3Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 4Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 9